论文部分内容阅读
Two of the five licensed drugs for Alzheimers Disease (AD), galantamine and rivastigmine,are naturally-derived cholinesterase inhibitors (ChEIs), while Huperzine A is a dual ChEI and NMDA receptor antagonist.